Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Revenue of Reneo Pharmaceuticals, Inc. (RPHM)
Revenue in 2023 (TTM): $
According to Reneo Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Reneo Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-525,000 | $-82,233,000 | $-77,388,000 | $-77,388,000 |
| 2022 | $ | $-529,000 | $-53,760,000 | $-51,955,000 | $-50,062,000 |
| 2021 | $ | $-50,000 | $-39,768,000 | $-39,770,000 | $-39,770,000 |
| 2020 | $ | $-37,000 | $-19,515,000 | $-19,465,000 | $-19,465,000 |
| 2019 | $ | $-34,000 | $-15,439,000 | $-12,436,000 | $-12,436,000 |